NCT04765709 2025-12-16
BRIDGE
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
Clinical Trials
25 trialsNCT05583110 2025-12-10
TrasTUCAN
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT02585388 2023-09-06
CHEOPS
ARCAGY/ GINECO GROUP
Phase 2 Terminated
NCT02229149 2022-12-02
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
US Oncology Research
Phase 2 Terminated
NCT03891173 2022-08-12
A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
Helix BioPharma Corporation
Phase 2 Terminated
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT02985203 2020-03-12
Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2 Terminated
NCT02117024 2020-02-05
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Heat Biologics
Phase 2 Terminated
NCT00130507 2019-02-26
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT01185509 2019-01-23
Trastuzumab and Vinorelbine in Advanced Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03358004 2018-10-05
VICTOR3
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT02919462 2018-01-16
HighTySy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT00194792 2017-07-11
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
University of Washington
Phase 2 Terminated
NCT00088985 2017-06-20
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00176488 2017-03-23
Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00597116 2016-10-10
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Sanofi
Phase 2 Terminated
NCT00754702 2015-09-28
Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
University Hospital of Crete
Phase 2 Terminated
NCT00391586 2015-08-17
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01161368 2015-08-13
A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients
Central European Cooperative Oncology Group
Phase 2 Terminated
NCT00694200 2015-05-29
Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT01038037 2014-12-04
Lung-TRIO
Vejle Hospital
Phase 2 Terminated
NCT00545948 2014-07-21
TOP0703
Duke University
Phase 2 Terminated
NCT00709618 2014-07-14
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
GlaxoSmithKline
Phase 2 Terminated
NCT00453635 2012-03-13
Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00403988 2008-11-04
Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (HerceptinĀ®) in Advanced Breast Carcinoma
American University of Beirut Medical Center
Phase 2 Terminated